For Toronto-based Dose Biosystems, a focus on researching and developing the next generation of probiotics brings a hiring challenge: finding and onboarding highly specialized talent. Coming directly from doctoral programs, new employees encounter an unfamiliar environment that requires new skills and different ways of working.

Quebec entrepreneur and former Mitacs intern Azadeh Dastmalchi developed a medical-grade smartwatch after struggling to find a device that could help her father monitor his hypertension. Now, in addition to targeting the one in three adults suffering from high blood pressure in North America, her company VitalTracer is pivoting its solution to assist with early detection and monitoring of COVID-19 symptoms.

Gum disease is a condition that shows up in 85 percent of cats and dogs before the age of four. Without proper treatment, the illness is painful and can lead to other health issues such as heart or kidney disease.

To improve the health of pets and prevent the issue, Quebec entrepreneur Andrée-Ann Adam has been working on a first-of-its-kind, all-natural dental gel.

A global pandemic didn’t stop Toronto entrepreneur Raghavender Sahdev from innovating. On the contrary, he spent the time propelling his start-up, NuPort Robotics, Canada’s first autonomous trucking company, which will help advance Canada’s trucking industry far into the future by using eco-friendly, self-driving electric trucks for short-haul shuttle runs between distribution centres, warehouses, and ports.

Who could have foreseen that humanitarian activities during the 2010 earthquake in Haiti would, 10 years later, guide the way for researchers, entrepreneurs and Mitacs interns during the COVID-19 crisis?

During his deployment at a Red Cross field hospital after the earthquake, Dr. Abdo Shabah saw the potential for greater use of technology in emergency health interventions.

When Gurudeeban Selvaraj and Satyavani Kaliamurthi came to Canada in 2019, they had no idea they would be creating both a preventative vaccine and a curing drug to address the millennium’s biggest pandemic.

As of May 27, 2020, there have been 2,925,466 infected COVID-19 patients reported worldwide, with a total of 355,727 deaths. The rapid progression of the COVID-19 pandemic has raised concerns regarding the short supply of medical equipment needed to control the rate of transmission and mortality. In most developing countries, transporting vaccines can be difficult without the proper storage technologies, since vaccines and equipment can spoil in high temperatures.

According to the Public Health Agency of Canada, the total number of COVID-19 cases reached a high of 71,486 as of May 13, 2020 — with Ontario and Quebec collectively accounting for 83% of all cases and 92% of the Canadian death toll. With a mortality rate of 3.4%, COVID-19 has created an unprecedented — and growing — demand for a vaccine.

With the spread of COVID-19, a leading University of Alberta research team has developed an innovative coating capable of killing viruses.

Buddy is as old as maple syrup, and it’s not friendly. This burned-Tootsie-Roll taste can ruin syrup flavour and is undetectable until sap is processed — far too late for small producers to recoup costs.

The annual cost of buddy, which the Ontario Maple Syrup Producers Association (OMSPA) estimates can reach into the millions, is a lot of liquid gold for small producers who are forced to sell buddy product at highly reduced rates. To avoid the risk, some producers stop production too early in the season, missing the opportunity to make high-quality syrup.